You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

metastatic breast cancer, vinorelbin, cisplatin, disulfiram

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Breast Cancer Trial in Bratislava (Disulfiram, Vinorelbin, Cisplatin)

Recruiting
  • Metastatic Breast Cancer
  • Bratislava, Slovakia
  • +1 more
Mar 2, 2021

Breast Tumor Female, Metastatic Breast Cancer Trial in Olomouc (Disulfiram)

Recruiting
  • Breast Neoplasm Female
  • Metastatic Breast Cancer
  • Olomouc, Czechia
    University Hospital Olomouc
Aug 2, 2022

Triple-negative Breast Cancer Trial in Shanghai (Chidamide combined with Cisplatin)

Recruiting
  • Triple-negative Breast Cancer
  • Chidamide combined with Cisplatin
  • Shanghai, China
  • +1 more
Apr 19, 2022

Locally Recurrent/Metastatic Triple Negative Breast Cancer Trial in United States (radiation, drug, procedure)

Recruiting
  • Locally Recurrent/Metastatic Triple Negative Breast Cancer
  • external beam radiation therapy
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Aug 8, 2022

Triple-Negative Breast Cancer, Breast Cancer Trial in United States (Romidepsin, Cisplatin, Nivolumab)

Active, not recruiting
  • Triple-Negative Breast Cancer
  • Breast Cancer
  • Fairway, Kansas
  • +6 more
Nov 19, 2021

Triple Negative Breast Cancer Trial in Shanghai (Cisplatin, Nab-paclitaxel, Pembrolizumab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 18, 2022

Triple-negative Metastatic Breast Cancer Trial in Boston (Cisplatin, AZD1775)

Completed
Has Results
  • Triple-negative Metastatic Breast Cancer
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Oct 29, 2021

Breast Cancer Trial in Shanghai (nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1))

Recruiting
  • Breast Cancer
  • nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 3, 2021

Metastatic Breast Cancer Trial in Beijing (Vinorelbine 40mg, Toripalimab 240mg, Bevacizumab 5 mg/kg)

Recruiting
  • Metastatic Breast Cancer
  • Vinorelbine 40mg
  • +5 more
  • Beijing, Beijing, China
  • +1 more
Feb 9, 2022

Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer Trial in Seattle (Veliparib,

No longer available
  • Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation
  • Triple-Negative Breast Cancer
  • Seattle, Washington
    Seattle Cancer Care Allliance
Jul 14, 2021

Metastatic Breast Cancer Trial in Amsterdam (Nivolumab, Cisplatin, Low dose doxorubicin)

Recruiting
  • Metastatic Breast Cancer
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek
Mar 21, 2022

Breast Cancer Trial in Dallas (Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis)

Recruiting
  • Breast Cancer
  • Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis
  • Dallas, Texas
    Baylor University Medical Center, Baylor Charles A Sammons Cance
Oct 7, 2021

Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Ureter Urothelial

Active, not recruiting
  • Metastatic Bladder Urothelial Carcinoma
  • +3 more
  • Phoenix, Arizona
  • +38 more
Jul 13, 2022

Metastatic Breast Cancer Trial in France (AZD2014, AZD4547, AZD5363)

Active, not recruiting
  • Metastatic Breast Cancer
  • Angers, France
  • +24 more
Mar 8, 2022

Triple-negative Breast Cancer Trial in Shanghai (HX008+Cisplatin+Gemcitabine)

Unknown status
  • Triple-negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 8, 2021

Metastatic BRCA-Associated Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Tumor in the Brain Trial in

Active, not recruiting
  • Metastatic BRCA-Associated Breast Carcinoma
  • +5 more
  • Anchorage, Alaska
  • +815 more
Aug 5, 2022

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma Trial in Worldwide (5-Fluorouracil

Recruiting
  • Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
  • 5-Fluorouracil (5-FU)
  • +11 more
  • Scottsdale, Arizona
  • +41 more
Jan 19, 2023

Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal

Active, not recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • +10 more
  • Birmingham, Alabama
  • +324 more
Jun 28, 2022

Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer Trial in Worldwide (Combination of NKTR-214 + nivolumab)

Completed
  • Melanoma
  • +6 more
  • Combination of NKTR-214 + nivolumab
  • La Jolla, California
  • +57 more
Jun 22, 2022

Chemo;Advanced Gastric Cancer;Cisplatin;Disulfiram Trial in Hangzhou (disulfiram and cisplatin, cisplatin)

Not yet recruiting
  • Chemotherapy；Advanced Gastric Cancer；Cisplatin；Disulfiram
  • Hangzhou, Zhejiang, China
    Hangzhou first people's Hospital
Dec 26, 2022

Eribulin-Based Regimen Versus Other Chemotherpy in

Active, not recruiting
  • Breast Cancer
  • Eribulin-Based Regimen
  • +2 more
  • Fuzhou, Fujian, China
    Fujian Cancer Hospital
Jul 18, 2023

HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response Trial in Beijing (Camrelizumab with vinorelbine

Recruiting
  • HER2-negative Breast Cancer
  • +5 more
  • Camrelizumab with vinorelbine and cisplatin
  • Beijing, Beijing, China
    Peking University First Hospital
Oct 15, 2022

Urothelial Carcinoma Trial in United States (Gemcitabine, Cisplatin, Ipilimumab)

Completed
Has Results
  • Urothelial Carcinoma
  • Duarte, California
  • +7 more
Jul 7, 2022

Biliary Tract Cancer, DNA Damage Repair Deficiency Trial in Seoul (Durvalumab, Olaparib)

Recruiting
  • Biliary Tract Cancer
  • DNA Damage Repair Deficiency
  • Seoul, Korea, Republic of
    Asan Medical Center
Apr 8, 2022

Triple-negative Breast Cancer Trial in Shanghai (chidamide, camrelizumab, carboplatin)

Not yet recruiting
  • Triple-negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 25, 2022